introduction to ISA
ISA Pharmaceuticals develops targeted, rationally designed immunotherapeutics for the treatment of cancer and persistent virus infections.
feature
ISA104 for chronic Hepatitis B is in a phase 1 clinical testing. This HEB-PEP trial, run by the Erasmus MC, is currently recruiting patients. Read more.
![](https://www.isa-pharma.com/wp-content/uploads/2018/12/gradient_line_2x.jpg)
![](https://www.isa-pharma.com/wp-content/uploads/2018/12/gradient_line_2x.jpg)